Skip to main content

Table 1 Hepatitis B vaccination trials

From: Preventing primary liver cancer: the HBV vaccination project in the Gambia (West Africa)

Location

No. of subjects

Year of recruitment/ year of Follow up

Prevalence HBsAg

Non-vaccinated/ vaccinated population

Efficacy

Relative Risk of developing HCC

Non-vaccinated/ vaccinated population

The Gambia*

>60000

1986-1990/ 9 yrs

10% > 1%

94%

Expected 2017

China*

(Qidong)>38000

1984-1990/ 11 yrs

7,1% > 1.66%

75%

Expected >2015

Taiwan ♦

1984

9.8% in 1984 > 0.7% in 1999

84%

0.31â– 

  1. *HBV vaccination trials programme [16, 7]
  2. ♦Universal vaccination programme [11]
  3. â– 64 HCC among vaccinees in 37709304 person-years versus 444 HCC in unvaccinated subjects in 78496406 person-years [11]